(Q33933475)

English

Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 July 2017

Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention (English)

1 reference

Europe PubMed Central

30 July 2017

Jolanta M Siller-Matula

object named as

Jolanta M Siller-Matula

1

0 references

object named as

Jacek Kubica

8

0 references

object named as

Gerald Maurer

5

0 references

Tomasz Grzybowski

7

object named as

Tomasz Grzybowski

1 reference

Europe PubMed Central

30 July 2017

2

object named as

Irene M Lang

1 reference

Europe PubMed Central

30 July 2017

9

object named as

Bernd Jilma

1 reference

Europe PubMed Central

30 July 2017

Marek Koziński

4

object named as

Marek Kozinski

1 reference

Europe PubMed Central

30 July 2017

author name string

Thomas Neunteufl

3

1 reference

Europe PubMed Central

30 July 2017

Katarzyna Linkowska

6

1 reference

Europe PubMed Central

30 July 2017

language of work or name

0 references

publication date

22 July 2014

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

9

1 reference

Europe PubMed Central

30 July 2017

7

1 reference

Europe PubMed Central

30 July 2017

e102701

1 reference

Europe PubMed Central

30 July 2017

copyright license

Creative Commons Attribution 4.0 International

22 July 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Response variability to P2Y12 receptor inhibitors: expectations and reality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

Genetic determinants of platelet response to clopidogrel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

Cytochrome p-450 polymorphisms and response to clopidogrel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

Clinical end points in coronary stent trials: a case for standardized definitions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

5 July 2018

Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0102701

21 January 2018

The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0102701

21 January 2018

Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0102701

21 January 2018

Effect of Paraoxonase-1 Polymorphism on Clinical Outcomes in Patients Treated With Clopidogrel After an Acute Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0102701

21 January 2018

Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0102701

21 January 2018

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0102701

21 January 2018

Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0102701

21 January 2018

The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0102701

21 January 2018

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0102701

21 January 2018

Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0102701

21 January 2018

Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106864

29 October 2018

Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0102701

21 January 2018

Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0102701

21 January 2018

Paraoxonase-1 is a major determinant of clopidogrel efficacy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25051347

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting

1 reference

https://pubmed.ncbi.nlm.nih.gov/25051347

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses

1 reference

https://pubmed.ncbi.nlm.nih.gov/25051347

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship between paraoxonase Q192R gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention

1 reference

https://pubmed.ncbi.nlm.nih.gov/25051347

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CYP2C19 But Not PON1 Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Post–Myocardial Infarction Patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25051347

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diurnal variation in platelet inhibition by clopidogrel

1 reference

https://pubmed.ncbi.nlm.nih.gov/25051347

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin

1 reference

https://pubmed.ncbi.nlm.nih.gov/25051347

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hemorrhagic Complications Associated With Aspirin

1 reference

https://pubmed.ncbi.nlm.nih.gov/25051347

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Continuous thrombin infusion leads to a bleeding phenotype in sheep

1 reference

https://pubmed.ncbi.nlm.nih.gov/25051347

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/25051347

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days

1 reference

https://pubmed.ncbi.nlm.nih.gov/25051347

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0102701

1 reference

Europe PubMed Central

30 July 2017

2014PLoSO...9j2701S

0 references

release_f42mzy3af5hw7d4sbubgwbaeji

1 reference

https://api.fatcat.wiki/v0/release/f42mzy3af5hw7d4sbubgwbaeji

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33933475&oldid=1987742184"